Standard BioTools vs Tango Therapeutics
LAB and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LAB and TNGX compare
Tango Therapeutics is the larger company, worth 17 times as much as Standard BioTools ($4.3B against $252M).
Standard BioTools grew revenue faster over the last twelve months (−4.8% versus −100% for Tango Therapeutics).
Standard BioTools scores higher on the StockData Score (12 against 8 for Tango Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LAB | TNGX |
|---|---|---|
| Size and price | ||
| Market cap | $252M | $4.3B |
| Share price | $0.643 | $25.73 |
| Change, 1 year | −45.0% | 224% |
| Change, 5 years | −85.7% | 115% |
| Beta (5Y) | 1.53 | 1.18 |
| Employees | 389 | 137 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 4 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 2.9× | – |
| P/S | 3.0× | – |
| P/B | 0.5× (better) | 4.4× |
| FCF yield | −32.7% | −3.5% (better) |
| Fair value | $4.90 | – |
| Margin of safety | 86.9% | – |
| Growth | ||
| Revenue growth (TTM) | −4.8% (better) | −100% |
| Revenue growth, 5Y average | −9.2% | 52.1% (better) |
| Profitability | ||
| Gross margin | 50.5% | – |
| Operating margin | −113% | – |
| Net margin | 100% | – |
| FCF margin | −97.6% | – |
| Return on equity | 17.6% (better) | −36.5% |
| Return on invested capital | −60.8% (better) | −3646% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.10 | 39.45 (better) |
| Altman Z-score | −0.34 | 48.20 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.4% | 127% |
| Held by insiders | 70.2% | 11.7% |
| Insider net buying, 12 months | $550K (better) | −$8.0M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 1.9% | 32.4% |
Go deeper
- LAB stock overview
- LAB income statement
- LAB valuation and score
- TNGX stock overview
- TNGX income statement
- TNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.